The enhanced in vivo activity of the combination of a MEK and a PI3K inhibitor correlates with [18F]-FLT PET in human colorectal cancer xenograft tumour-bearing mice

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Haagensen, Emma J ^a   Thomas, Huw D ^a   Wilson, Ian ^a   Harnor, Suzannah J ^b   Payne, Sara L ^b   Rennison, Tommy ^b   Smith, Kate M ^b   Maxwell, Ross J ^a   Newell, David R ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE F 18; ANTINEOPLASTIC AGENT; GCD 094; INITIATION FACTOR 4E BINDING PROTEIN 1; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PICTILISIB; PROTEIN S6; UNCLASSIFIED DRUG;

\GCD 094; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MONOTHERAPY; MOUSE; NON INVASIVE MEASUREMENT; NONHUMAN; PHARMACODYNAMICS; POSITRON EMISSION TOMOGRAPHY; TUMOR XENOGRAFT;

ANIMALS; ANTIVIRAL AGENTS; BENZAMIDES; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DIDEOXYNUCLEOSIDES; DIPHENYLAMINE; DRUG SYNERGISM; FEMALE; HETEROGRAFTS; HUMANS; INDAZOLES; MAP KINASE KINASE KINASES; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; POSITRON-EMISSION TOMOGRAPHY; PROTO-ONCOGENE PROTEINS C-AKT; SULFONAMIDES;

EID: 84892405979     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0081763     Document Type: Article

References (59)

1. Markman B, Tao JJ, Scaltriti M (2013) PI3K pathway inhibitors: better not left alone. Curr Pharm Des 19: 895-906.
2. Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, et al. (2008) The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-yl- methyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer. Journal of Medicinal Chemistry 51: 5522-5532.
3. Edgar KA, Wallin JJ, Berry M, Lee LB, Prior WW, et al. (2010) Isoform-Specific Phosphoinositide 3-Kinase Inhibitors Exert Distinct Effects in Solid Tumors. Cancer Research 70: 1164-1172.
4. Wallin JJ, Guan J, Prior WW, Lee LB, Berry L, et al. (2012) GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death In Vitro and In Vivo. Clinical Cancer Research 18: 3901-3911.
5. O'Brien C, Wallin JJ, Sampath D, GuhaThakurta D, Savage H, et al. (2010) Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 In Breast Cancer Preclinical Models. Clinical Cancer Research 16: 3670-3683.
6. Sos ML, Fischer S, Ullrich R, Peifer M, Heuckmann JM, et al. (2009) Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci USA 106: 18351-18356.
7. Salphati L, Pang J, Plise EG, Chou B, Halladay JS, et al. (2011) Preclinical pharmacokinetics of the novel PI3K inhibitor GDC-0941 and prediction of its pharmacokinetics and efficacy in human. Xenobiotica 41: 1088-1099.
8. ClinicalTrials.gov website. Available: http://www.clinicaltrials.gov. Accessed 2012 Dec 10.
9. Moreno Garcia V, Baird RD, Shah KJ, Basu B, Tunariu N, et al. (2011) A phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase (PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma. J Clin Oncol 29: 3021.
10. Henderson YC, Chen Y, Frederick MJ, Lai SY, Clayman GL (2010) MEK Inhibitor PD0325901 Significantly Reduces the Growth of Papillary Thyroid Carcinoma Cells In vitro and In vivo. Mol Cancer Ther 9: 1968-1976.
11. Barrett SD, Bridges AJ, Dudley DT, Saltiel AR, Fergus JH, et al. (2008) The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorganic & Medicinal Chemistry Letters 18: 6501-6504.
12. Kinross KM, Brown DV, Kleinschmidt M, Jackson S, Christensen J, et al. (2011) In Vivo Activity of Combined PI3K/mTOR and MEK Inhibition in a KrasG12D;Pten Deletion Mouse Model of Ovarian Cancer. Molecular Cancer Therapeutics 10: 1440-1449.
13. Solit DB, Santos E, Pratilas CA, Lobo J, Moroz M, et al. (2007) 3′-Deoxy-3′-[18F]Fluorothymidine Positron Emission Tomography Is a Sensitive Method for Imaging the Response of BRAF-Dependent Tumors to MEK Inhibition. Cancer Research 67: 11463-11469.
14. Leyton J, Smith G, Lees M, Perumal M, Nguyen Q-d, et al. (2008) Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901. Molecular Cancer Therapeutics 7: 3112-3121.
15. Brown AP, Carlson, T C., Loi, C M., Graziano, M J. (2007) Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration. Cancer Chemother Pharmacol 59: 671-679.
16. Haura EB, Ricart AD, Larson TG, Stella PJ, Bazhenova L, et al. (2010) A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. Clinical Cancer Research 16: 2450-2457.
17. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, et al. (2008) Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14: 1351-1356.
18. Faber AC, Li D, Song Y, Liang M-C, Yeap BY, et al. (2009) Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proceedings of the National Academy of Sciences 106: 19503-19508.
19. Hoeflich KP, Merchant M, Orr C, Chan J, Den Otter D, et al. (2012) Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition. Cancer Research 72: 210-219.
20. Paproski RJ, Ng AML, Yao SYM, Graham K, Young JD, et al. (2008) The Role of Human Nucleoside Transporters in Uptake of 3′-Deoxy-3′- fluorothymidine. Molecular Pharmacology 74: 1372-1380.
21. Buck AK, Herrmann K, Shen C, Dechow T, Schwaiger M, et al. (2009) Molecular imaging of proliferation in vivo: Positron emission tomography with [18F]fluorothymidine. Methods 48: 205-215.
22. Sherley JL, Kelly TJ (1988) Regulation of human thymidine kinase during the cell cycle. Journal of Biological Chemistry 263: 8350-8358.
23. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, et al. (1998) Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4: 1334-1336.
24. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL (2002) Validation of FLT Uptake as a Measure of Thymidine Kinase-1 Activity in A549 Carcinoma Cells. Journal of Nuclear Medicine 43: 1210-1217.
25. Barthel H, Cleij MC, Collingridge DR, Hutchinson OC, Osman S, et al. (2003) 3-Deoxy-3′[18F]Fluorothymidine as a New Marker for Monitoring Tumor Response to Antiproliferative Therapy in Vivo with Positron Emission Tomography. Cancer Research 63: 3791-3798.
26. Buck AK, Schirrmeister H, Hetzel M, von der Heide M, Halter G, et al. (2002) 3-Deoxy-3-[18F]Fluorothymidine-Positron Emission Tomography for Noninvasive Assessment of Proliferation in Pulmonary Nodules. Cancer Research 62: 3331-3334.
27. Cobben DCP, Elsinga PH, Suurmeijer AJH, Vaalburg W, Maas B, et al. (2004) Detection and Grading of Soft Tissue Sarcomas of the Extremities with 18F-3Fluoro-3-Deoxy-l-Thymidine. Clinical Cancer Research 10: 1685-1690.
28. Pantaleo MA, Nannini M, Maleddu A, Fanti S, Ambrosini V, et al. (2008) Conventional and novel PET tracers for imaging in oncology in the era of molecular therapy. Cancer Treatment Reviews 34: 103-121.
29. Chalkidou A, Landau DB, Odell EW, Cornelius VR, O'Doherty MJ, et al. (2012) Correlation between Ki-67 immunohistochemistry and 18F-Fluorothymidine uptake in patients with cancer: A systematic review and meta-analysis. European Journal of Cancer 48: 3499-3513.
30. Fuereder T, Wanek T, Pflegerl P, Jaeger-Lansky A, Hoeflmayer D, et al. (2011) Gastric Cancer Growth Control by BEZ235 In Vivo Does Not Correlate with PI3K/mTOR Target Inhibition but with [18F]FLT Uptake. Clinical Cancer Research 17: 5322-5332.
31. Cawthorne C, Burrows N, Gieling RG, Morrow CJ, Forster D, et al. (2013) [18F]-FLT Positron Emission Tomography Can Be Used to Image the Response of Sensitive Tumors to PI3-Kinase Inhibition with the Novel Agent GDC-0941. Molecular Cancer Therapeutics 12: 819-828.
32. Pio B, Park C, Pietras R, Hsueh W-A, Satyamurthy N, et al. (2006) Usefulness of 3-[F-18]Fluoro-3-deoxythymidine with Positron Emission Tomography in Predicting Breast Cancer Response to Therapy. Molecular Imaging and Biology 8: 36-42.
33. Kenny L, Coombes RC, Vigushin D, Al-Nahhas A, Shousha S, et al. (2007) Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3-deoxy-3-[18F]fluorothymidine positron emission tomography. European Journal of Nuclear Medicine and Molecular Imaging 34: 1339-1347.
34. Hoeben BAW, Troost EGC, Span PN, van Herpen CML, Bussink J, et al. (2013) 18F-FLT PET During Radiotherapy or Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma Is an Early Predictor of Outcome. Journal of Nuclear Medicine 54: 532-540.
35. Desar IM, Gilles R, van Herpen CM, Timmer-Bonte AJ, Cantarini MV, et al. (2012) (18)F-FLT-PET for Response Evaluation of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with Solid Tumors. World J Nucl Med 11: 65-69.
36. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, et al. (2010) Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102: 1555-1577.
37. Baker SJ, Goldsmith PJ, Hancox TC, Pegg NA, Price S, et al. (2007) Preparation of Thienopyrimidine Derivatives as PI3 Kinase Inhibitors. In: 2007:1237434 SS, editor: F.Hoffman-La Roche AG.
38. Haagensen EJ, Kyle S, Beale GS, Maxwell RJ, Newell DR (2012) The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition. Br J Cancer 106: 1386-1394.
39. Cawthorne C, Burrows N, Gieling RG, Morrow CJ, Forster D, et al. (2013) [18F]-FLT positron emission tomography can be used to image the response of sensitive tumours to PI3-kinase inhibition with the novel agent GDC-0941. Mol Cancer Ther 12: 819-828.
40. Rexer BN, Ghosh R, Arteaga CL (2009) Inhibition of PI3K and MEK: It Is All about Combinations and Biomarkers. Clinical Cancer Research 15: 4518-4520.
41. Bermudez O, Marchetti S, Pages G, Gimond C (2008) Post-translational regulation of the ERK phosphatase DUSP6/MKP3 by the mTOR pathway. Oncogene 27: 3685-3691.
42. Roux PP, Ballif BA, Anjum R, Gygi SP, Blenis J (2004) Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proceedings of the National Academy of Sciences of the United States of America 101: 13489-13494.
43. Duong H-Q, Kim HJ, Kang HJ, Seong Y-S, Bae I (2012) ZSTK474, a PI3K inhibitor, suppresses proliferation and sensitizes human pancreatic adenocarcinoma cells to gemcitabine. Oncol Rep 27: 182-188.
44. Biggs WH, Meisenhelder J, Hunter T, Cavenee WK, Arden KC (1999) Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proceedings of the National Academy of Sciences 96: 7421-7426.
45. Greer EL, Brunet A (2005) FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 24: 7410-7425.
46. Yang J-Y, Zong CS, Xia W, Yamaguchi H, Ding Q, et al. (2008) ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol 10: 138-148.
47. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, et al. (2000) Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes & Development 14: 2501-2514.
48. Zhu J, Blenis J, Yuan J (2008) Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1. Proceedings of the National Academy of Sciences 105: 6584-6589.
49. She Q-B, Solit DB, Ye Q, O'ÄôReilly KE, Lobo J, et al. (2005) The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 8: 287-297.
50. Harada H, Andersen JS, Mann M, Terada N, Korsmeyer SJ (2001) p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proceedings of the National Academy of Sciences 98: 9666-9670.
51. Harada H, Becknell B, Wilm M, Mann M, Huang LJ-s, et al. (1999) Phosphorylation and Inactivation of BAD by Mitochondria-Anchored Protein Kinase A. Molecular Cell 3: 413-422.
52. Tan Y, Ruan H, Demeter MR, Comb MJ (1999) p90RSK Blocks Bad-mediated Cell Death via a Protein Kinase C-dependent Pathway. Journal of Biological Chemistry 274: 34859-34867.
53. Manning BD, Cantley LC (2007) AKT/PKB Signaling: Navigating Downstream. Cell 129: 1261-1274.
54. Kelly CJ, Hussien K, Muschel RJ (2012) 3D tumour spheroids as a model to assess the suitability of [18F]FDG-PET as an early indicator of response to PI3K inhibition. Nuclear Medicine and Biology 39: 986-992.
55. Nguyen Q-D, Perumal M, Waldman TA, Aboagye EO (2011) Glucose metabolism measured by [18F]fluorodeoxyglucose positron emission tomography is independent of PTEN/AKT status in human colon carcinoma cells. Translational Oncology 4: 241-248.
56. Baudy A, Dogan T, Flores-Mercado J, Hoeflich K, Su F, et al. (2012) FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973. EJNMMI Research 2: 22.
57. Zhang CC, Yan Z, Li W, Kuszpit K, Painter CL, et al. (2012) [18F]FLT PET Imaging Does Not Always Light Up Proliferating Tumor Cells. Clinical Cancer Research 18: 1303-1312.
58. Eliot T . McKinley, Gregory D . Ayers, R. Adam Smith, Samir A . Saleh, Ping Zhao, et al. (2013) Limits of [18F]-FLT PET as a Biomarker of Proliferation in Oncology. PLoS ONE 8: e58938.
59. Ebenhan T, Honer M, Ametamey SM, Schubiger PA, Becquet M, et al. (2009) Comparison of [18F]-Tracers in Various Experimental Tumor Models by PET Imaging and Identification of an Early Response Biomarker for the Novel Microtubule Stabilizer Patupilone. Molecular Imaging and Biology 11: 308-321.